Non-ST-elevation myocardial infarction, or NSTEMI, is a common yet complex form of heart attack affecting thousands each year. While doctors routinely assess heart function and coronary artery health in these patients, the combined impact of reduced heart pumping efficiency and blocked arteries on long-term survival has remained a critical gap in understanding. New research from Denmark, published this month in the Journal of the American College of Cardiology: Advances, offers the first comprehensive look at how these two factors interact to influence prognosis after a first-time NSTEMI.
A reduced left ventricular ejection fraction (LVEF) and significant coronary heart disease (CHD) are both linked to increased mortality. However, it remained unclear how the combination of these two factors impacts prognosis following a non-ST-elevation myocardial infarction (NSTEMI). A recent study aimed to address this question.
Sebastian Kaulitzki/stock.adobe.com
Patients experiencing a non-ST-elevation myocardial infarction (NSTEMI) represent a large and diverse group in clinical practice. Understanding the factors that influence their long-term outcomes is crucial for improving care. These patients routinely undergo echocardiography to assess their left ventricular ejection fraction (LVEF) and coronary angiography to evaluate the extent of coronary heart disease (CHD). Both LVEF and CHD have independently been established as risk factors for increased mortality.
Now, Danish researchers at Aarhus University Hospital have conducted the first study to examine the combined prognostic impact of LVEF and CHD on outcomes after a first-time NSTEMI according to research published in the Journal of the American College of Cardiology: Advances.
The prospective cohort study included data from patients registered in the Western Denmark Heart Registry. Researchers enrolled adults with obstructive CHD who experienced their first NSTEMI between 2010 and 2021 and subsequently underwent coronary angiography (n=8770). Patients with a prior myocardial infarction, those who had undergone percutaneous coronary intervention or bypass surgery, or those with non-obstructive CHD were excluded from the study.
Participants were categorized based on their LVEF (greater than 50%, 41–50%, and less than or equal to 40%) and the extent of their CHD (single-vessel, two-vessel, or three-vessel disease). The researchers then compared these data to a control group from the general population, matched for age and sex and with no documented history of myocardial infarction.
The primary endpoint of the study was all-cause mortality at five years. This research aims to provide a more refined risk assessment for NSTEMI patients, potentially leading to more tailored treatment strategies and improved survival rates.
